دورية أكاديمية
أعرض في EDS

Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability.

التفاصيل البيبلوغرافية
العنوان: Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability.
المؤلفون: Cozijnsen MA; Department of Paediatric Gastroenterology, Erasmus University Medical Centre-Sophia Children's Hospital, P.O. Box 2060, 3000 CB, Rotterdam, The Netherlands., Samsom JN; Laboratory of Paediatrics, Erasmus University Medical Centre-Sophia Children's Hospital, Rotterdam, The Netherlands., de Ridder L; Department of Paediatric Gastroenterology, Erasmus University Medical Centre-Sophia Children's Hospital, P.O. Box 2060, 3000 CB, Rotterdam, The Netherlands. l.deridder@erasmusmc.nl.
المصدر: Paediatric drugs [Paediatr Drugs] 2018 Feb; Vol. 20 (1), pp. 19-28.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer International Country of Publication: Switzerland NLM ID: 100883685 Publication Model: Print Cited Medium: Internet ISSN: 1179-2019 (Electronic) Linking ISSN: 11745878 NLM ISO Abbreviation: Paediatr Drugs Subsets: MEDLINE
أسماء مطبوعة: Publication: June 2010- : Cham, Switzerland : Springer International
Original Publication: Auckland ; Philadelphia : Adis International, c1999-
مواضيع طبية MeSH: Biosimilar Pharmaceuticals/*therapeutic use , Crohn Disease/*drug therapy , Tumor Necrosis Factor-alpha/*antagonists & inhibitors, Adolescent ; Biosimilar Pharmaceuticals/pharmacology ; Child ; Child, Preschool ; Crohn Disease/pathology ; Humans ; Treatment Outcome
مستخلص: Antibodies directed to tumour necrosis factor-α (TNF-α) are very effective in treating paediatric Crohn's disease (CD). Over the last few years, research has provided important new insights into how to optimise this treatment's effectiveness. Research on predictors for anti-TNF treatment responsiveness has revealed potential markers, but data on their accuracy in paediatric CD patients are lagging behind. Also, new evidence has become available on the safety profile of anti-TNF antibodies that suggests the assumed increased malignancy risk seen in patients on anti-TNF and thiopurine combination treatment may be linked more to thiopurine use and not to anti-TNF treatment. In addition, the early results of CT-P13, an infliximab biosimilar, in CD patients confirm the expected similarity with its originator. Thus, the effectiveness of anti-TNF antibody treatment is slowly improving, its malignancy risk is lower than assumed, and its costs are reduced by the introduction of equally effective biosimilars. Together, these trends allow for a more prominent role for anti-TNF antibodies in future treatment of paediatric CD.
References: Am J Gastroenterol. 2000 Nov;95(11):3189-94. (PMID: 11095340)
Inflamm Bowel Dis. 2004 Sep;10(5):661-5. (PMID: 15472532)
Nat Med. 2017 May;23 (5):579-589. (PMID: 28368383)
Aliment Pharmacol Ther. 2014 May;39(10):1126-35. (PMID: 24689499)
PLoS One. 2013 Oct 14;8(10):e76235. (PMID: 24155895)
J Crohns Colitis. 2016 Feb;10 (2):127-32. (PMID: 26721942)
BioDrugs. 2017 Feb;31(1):37-49. (PMID: 28035633)
Inflamm Bowel Dis. 2009 Mar;15(3):388-94. (PMID: 19023899)
Clin Immunol. 2009 Nov;133(2):208-17. (PMID: 19646928)
Inflamm Bowel Dis. 2014 Feb;20(2):291-300. (PMID: 24374875)
Ann Rheum Dis. 2013 Oct;72(10):1613-20. (PMID: 23687260)
Inflamm Bowel Dis. 2012 Mar;18(3):401-8. (PMID: 21936028)
J Pediatr Gastroenterol Nutr. 2017 Apr;64(4):580-585. (PMID: 28079601)
Inflamm Bowel Dis. 2010 Dec;16(12):2090-8. (PMID: 20848504)
Gastroenterology. 2012 Aug;143(2):365-74.e2. (PMID: 22562021)
J Pediatr Gastroenterol Nutr. 2012 Jun;54(6):830-7. (PMID: 22584748)
Dig Liver Dis. 2016 Mar;48(3):260-6. (PMID: 26699828)
Curr Med Res Opin. 2013 May;29(5):483-93. (PMID: 23438483)
Am J Gastroenterol. 2006 Dec;101(12):2769-76. (PMID: 17026564)
J Pediatr Gastroenterol Nutr. 2016 May;62(5):715-22. (PMID: 26551317)
N Engl J Med. 2010 Apr 15;362(15):1383-95. (PMID: 20393175)
Gastroenterology. 2005 Feb;128(2):376-92. (PMID: 15685549)
Pharmacogenetics. 2002 Apr;12(3):183-90. (PMID: 11927833)
Inflamm Bowel Dis. 2015 Apr;21(4):951-61. (PMID: 25723615)
Clin Gastroenterol Hepatol. 2009 Aug;7(8):874-81. (PMID: 19558997)
Gastroenterology. 2000 May;118(5):859-66. (PMID: 10784585)
Gut. 2014 Nov;63(11):1721-7. (PMID: 24474383)
Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. (PMID: 17324398)
Aliment Pharmacol Ther. 2004 Aug 1;20(3):303-10. (PMID: 15274667)
Gastroenterology. 2001 Nov;121(5):1088-94. (PMID: 11677200)
J Pediatr Gastroenterol Nutr. 2017 Jan;64(1):47-55. (PMID: 27657882)
Genome Med. 2013 Jun 28;5(6):59. (PMID: 23809696)
Scand J Gastroenterol. 2013 May;48(5):543-51. (PMID: 23477356)
J Crohns Colitis. 2009 Jun;3(2):47-91. (PMID: 21172250)
Aliment Pharmacol Ther. 2003 Aug 15;18(4):425-31. (PMID: 12940928)
J Pediatr Gastroenterol Nutr. 2009 Aug;49(2):183-90. (PMID: 19561542)
Am J Gastroenterol. 2016 Dec;111(12 ):1816-1822. (PMID: 27596696)
J Crohns Colitis. 2014 Oct;8(10):1179-207. (PMID: 24909831)
Aliment Pharmacol Ther. 2008 May;27(9):765-70. (PMID: 18248655)
Aliment Pharmacol Ther. 2012 Mar;35(5):568-76. (PMID: 22251435)
BMJ Open Gastroenterol. 2016 Dec 22;3(1):e000123. (PMID: 28090335)
Inflamm Bowel Dis. 2010 Jun;16(6):953-61. (PMID: 19834970)
Am J Gastroenterol. 2013 Jan;108(1):99-105. (PMID: 23032984)
Gastroenterology. 2017 Jun;152(8):1901-1914.e3. (PMID: 28193515)
Gastroenterology. 2005 Sep;129(3):807-18. (PMID: 16143120)
Inflamm Bowel Dis. 2015 Feb;21(2):331-6. (PMID: 25625487)
Clin Gastroenterol Hepatol. 2011 Jan;9(1):36-41.e1. (PMID: 20888436)
Nat Med. 2014 Mar;20(3):313-8. (PMID: 24562382)
Inflamm Bowel Dis. 2016 Oct;22(10 ):2465-73. (PMID: 27580385)
J Pediatr Gastroenterol Nutr. 2015 Sep;61(3):e15. (PMID: 26111298)
Pharmacol Ther. 2008 Feb;117(2):244-79. (PMID: 18155297)
World J Gastroenterol. 2010 Jun 7;16(21):2609-15. (PMID: 20518082)
Lancet. 2017 Apr 29;389(10080):1710-1718. (PMID: 28259484)
Gastroenterology. 2011 Jan;140(1):221-30. (PMID: 20955706)
Gastroenterology. 2015 Jun;148(7):1320-9.e3. (PMID: 25724455)
World J Gastroenterol. 2014 Oct 21;20(39):14479-87. (PMID: 25339835)
N Engl J Med. 2004 Nov 11;351(20):2069-79. (PMID: 15537905)
J Crohns Colitis. 2015 Dec;9(12):1120-6. (PMID: 26351386)
Inflamm Bowel Dis. 2007 Nov;13(11):1323-32. (PMID: 17636564)
J Pediatr Gastroenterol Nutr. 2003 May;36(5):632-6. (PMID: 12717087)
Abdom Radiol (NY). 2017 Jan;42(1):141-151. (PMID: 27549100)
Lancet. 2017 Jun 10;389(10086):2304-2316. (PMID: 28502609)
Inflamm Bowel Dis. 2016 Jun;22(6):1370-7. (PMID: 27057683)
Inflamm Bowel Dis. 2011 Jan;17(1):423-39. (PMID: 20564651)
J Crohns Colitis. 2013 Oct;7(9):736-43. (PMID: 23200919)
Gastroenterology. 2008 Oct;135(4):1114-22. (PMID: 18725221)
Ann Rheum Dis. 2013 Oct;72(10):1605-12. (PMID: 23687259)
Gut. 2002 Feb;50(2):206-11. (PMID: 11788561)
Biochem Genet. 2016 Aug;54(4):476-486. (PMID: 27115882)
المشرفين على المادة: 0 (Biosimilar Pharmaceuticals)
0 (Tumor Necrosis Factor-alpha)
SCR Disease Name: Pediatric Crohn's disease
تواريخ الأحداث: Date Created: 20171029 Date Completed: 20180424 Latest Revision: 20220409
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC5775976
DOI: 10.1007/s40272-017-0266-9
PMID: 29079905
قاعدة البيانات: MEDLINE
الوصف
تدمد:1179-2019
DOI:10.1007/s40272-017-0266-9